Get started
Author

Hiroshi Inakura

Observed name: H. Inakura
ORCID: 0000-0001-9771-797X
Observed ORCID: 0000-0001-9771-797X
OpenAlex ID: A5084894194
The effect of surface modification of amorphous silica particles on NLRP3 inflammasome mediated IL-1β production, ROS production and endosomal rupture
2010 · Tomohiro Morishige, Yasuo Yoshioka, et al. · Biomaterials · 156
Suppression of nanosilica particle-induced inflammation by surface modification of the particles
2012 · Tomohiro Morishige, Yasuo Yoshioka, et al. · Archives of Toxicology · 56
Cytotoxicity of amorphous silica particles against macrophage-like THP-1 cells depends on particle-size and surface properties
2010 · T. Morishige, Y. Yoshioka, et al. · Die Pharmazie · 24
PDF
Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy
2010 · Tomohiro Morishige, Yasuo Yoshioka, et al. · Biomaterials · 16
Systemically Acting Diclofenac Sodium Patch for Control of Low Back Pain: A Randomized, Double-Blind, Placebo-Controlled Study in Japan
2023 · Toshihiko Taguchi, Shigeki Yamaguchi, et al. · Pain and Therapy · 14
PDF
A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III study
2023 · Tomoko Fujimoto, Takaaki Terahara, et al. · Journal of the American Academy of Dermatology · 13
Creation of a lysine-deficient LIGHT mutant with the capacity for site-specific PEGylation and low affinity for a decoy receptor
2010 · Tomohiro Morishige, Yasuo Yoshioka, et al. · Biochemical and Biophysical Research Communications · 11
LIGHT protein suppresses tumor growth by augmentation of immune response
2009 · Tomohiro Morishige, Yasuo Yoshioka, et al. · Immunology Letters · 9
Long‐term evaluation of the safety and efficacy of a novel 20% oxybutynin hydrochloride lotion for primary palmar hyperhidrosis: An open‐label extension study
2023 · Tomoko Fujimoto, Takaaki Terahara, et al. · The Journal of Dermatology · 6
A multicenter, randomized, double-blind, placebo-controlled, comparative study to evaluate the efficacy and safety of newly developed diclofenac patches in patients with cancer pain
2021 · Shigeki Yamaguchi, Takaaki Terahara, et al. · Pain · 4
A multicenter, randomized, double-blind, placebo-controlled, comparative study to evaluate the efficacy and safety of newly developed diclofenac patches in patients with cancer pain
2021 · Shigeki Yamaguchi, Takaaki Terahara, et al. · Pain · 3
Combined Efficacy of Systemically Acting Diclofenac Sodium Patch and Alpha-2-Delta Calcium Channel Ligand in Chronic Low Back Pain: Subanalysis of a Phase III Study
2023 · Shigeki Yamaguchi, Takaaki Terahara, et al. · Pain and Therapy · 1
PDF
Works count: 12
Citation count: 313
H-index: 8
I10-index: 7
Year
Topic
Type